A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study to Investigate the Effects of ACT-541468 on Nighttime Respiratory Function in Patients With Mild to Moderate Obstructive Sleep Apnea
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Feb 2019
At a glance
- Drugs Nemorexant (Primary)
- Indications Sleep apnoea syndrome
- Focus Therapeutic Use
- Sponsors Idorsia Pharmaceuticals
- 01 Feb 2019 Planned End Date changed from 30 Jun 2019 to 31 Jul 2019.
- 01 Feb 2019 Planned primary completion date changed from 30 Jun 2019 to 31 Jul 2019.
- 01 Feb 2019 Planned initiation date changed from 29 Jan 2019 to 24 Mar 2019.